絞り込み

16355

広告

「elotuzumab」の検索結果

135件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

How is patient care for multiple myeloma advancing?

Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.

Which therapies will move to the front line for multiple myeloma?

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.

Immunotherapy for the treatment of multiple myeloma.

Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.

FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.

A phase 2 safety study of accelerated elotuzumab infusion, over less than 1 hour, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma.

Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.

Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist.

Immune Therapies in Multiple Myeloma.

Progress and Paradigms in Multiple Myeloma.

Safety issues and managment of toxicities associated with new treatments for multiple myeloma.

Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.

An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.

Efficacy and safety of elotuzumab for the treatment of multiple myeloma.

Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.

Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
Sort by
※並べ替えは表示に時間がかかります